Tezepelumab Granted Priority Review By U S FDA prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Health, MILWAUKEE (PRWEB) June 13 2021 World Allergy Organization (WAO) serving its membership of professional allergy/immunology societies around the world dedicates World,World,Allergy,Week,2021,Launches,Today,to,Raise,Awareness,of,Anaphylaxis,medicine,medical news today,latest medical news,medical newsletters,current medical news,latest medicine news
MILWAUKEE, June 13, 2021 /PRNewswire-PRWeb/ World Allergy Organization (WAO), serving its membership of professional allergy/immunology societies around .
/PRNewswire/ Amgen (NASDAQ:AMGN) and AstraZeneca today announced detailed results for tezepelumab, a potential first-in-class treatment, from the pivotal.
Share this article
Share this article
THOUSAND OAKS, Calif., May 10, 2021 /PRNewswire/ Amgen (NASDAQ:AMGN) today announced its partner AstraZeneca (NASDAQ:AZN) submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for tezepelumab, a potential first-in-class medicine in severe asthma. The submission is supported by positive clinical trial results from the PATHFINDER clinical program including the pivotal NAVIGATOR Phase 3 trial, which demonstrated a statistically significant and clinically meaningful reduction in the annualized asthma exacerbation rate (AAER) in patients with severe, uncontrolled asthma compared to placebo.
1 Tezepelumab is the only biologic to consistently and significantly reduce AAER in a broad population of severe asthma patients irrespective of the baseline eosinophil counts across Phase 2 and Phase 3 clinical trials.